Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Genscript BiotechGNNSF +6.06%66 Gross Margin % is 51.14% as of Jun. 2026, which is 17% below its 10-year median of 61.56. GuruFocus rates GNNSF with a GF Score™ of 66/100 and a GF Value™ of $2.09 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 734 Biotechnology companies, Genscript Biotech ranks worse than 53.41% on this metric.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Genscript Biotech had a gross margin of 51.14% for the quarter that ended in Jun. 2026 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Genscript Biotech Gross Margin % Related Terms
Genscript Biotech Gross Margin % Historical Data
* Premium members only.
The historical data trend for Genscript Biotech's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GNNSF vs VRTX, REGN, RVMD: Gross Margin % Comparison
For the Biotechnology subindustry, Genscript Biotech's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genscript Biotech Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Genscript Biotech's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Genscript Biotech's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Genscript Biotech (GNNSF) has a Gross Margin % of 51.14% as of Jun. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Genscript Biotech and its competitors. This is 17% below median its historical median of 61.56. Over the past decade, Genscript Biotech's Gross Margin % has ranged from 45.77 to 68.63. According to the industry distribution chart, Genscript Biotech ranks #392 out of 734 companies in the Biotechnology industry, placing it in the top 53.4%.
Is Genscript Biotech's Gross Margin % too high?
Genscript Biotech's current Gross Margin % of 51.14% is 17% below median its 10-year median of 61.56. Over the past 10 years, this metric has ranged from a low of 45.77 to a high of 68.63. The Biotechnology industry median Gross Margin % is 60.92. Genscript Biotech's value of 51.14% is 16% below this industry median. Based on the distribution chart, Genscript Biotech ranks #392 out of 734 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Genscript Biotech has a GF Score™ of 66/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Genscript Biotech's Gross Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Genscript Biotech ranks #392 out of 734 companies for Gross Margin %. This places Genscript Biotech in the lower half of its industry. The industry median Gross Margin % is 60.92. Genscript Biotech's value of 51.14% is 16% below this benchmark. Historically, Genscript Biotech's own Gross Margin % has ranged from 45.77 to 68.63 over the past decade. While the company's 10-year median is 61.56 vs. the industry median of 60.92, Genscript Biotech has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.92, based on 734 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Genscript Biotech's current Gross Margin % of 51.14% is 16% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Genscript Biotech and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.92 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Genscript Biotech's current Gross Margin % is 51.14%, which is 17% below median its own 10-year median of 61.56. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genscript Biotech stock overvalued right now?
Based on GuruFocus' analysis, Genscript Biotech (GNNSF) is currently considered Significantly Overvalued. The stock's GF Value™ is $2.09, compared to a current price of $3.50 — trading 67.5% above its estimated fair value. The current Gross Margin % is 51.14%, which is 17% below median its 10-year median of 61.56 and 16% below the Biotechnology industry median of 60.92. Genscript Biotech's overall GF Score™ is 66/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Genscript Biotech (GNNSF), the current Gross Margin % is 51.14% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Genscript Biotech (GNNSF) Overvalued in 2026?
Based on GuruFocus' analysis, Genscript Biotech stock appears to be overvalued.
The current stock price of $3.50 is trading 67.5% above its estimated GF Value™ of $2.09.
GuruFocus considers Genscript Biotech to be Significantly Overvalued.
Key valuation signals for GNNSF:
Gross Margin %: 51.14% (17% below median its 10-year median of 61.56)
GF Value™: $2.09 vs. price of $3.50 (67.5% above fair value)
Industry Position: 16% below the Biotechnology median (#392 of 734)
No single metric tells the full story. See the GNNSF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
GenScript Biotech Corp is an investment holding company engaged in the manufacture and sale of life science research products and services, including life science services and products, biologics development services, and industrial synthetic biology products. Its segments include life science services and products, which generate maximum revenue and provide research services and products; biologics development services, which support the development of therapeutic antibodies and CGT products; industrial synthetic biology, which provides enzyme development and production using engineered microbial strains; and the operation unit, which provides shared services. It operates in Mainland China, which generates maximum revenue, U.S., Europe, and the Asia Pacific excluding Mainland China.
66GF Score
Get the complete analysis for GNNSF
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GNNSF has been successfully added to your 
